四药联合方案治疗新诊断多发性骨髓瘤:系统评价与Meta分析
该系统评价与Meta分析纳入7项随机对照试验共3716例新诊断多发性骨髓瘤患者,比较蛋白酶体抑制剂联合免疫调节药物方案基础上加用抗CD38单抗的四药方案与三药方案的疗效与毒性。四药方案提高总缓解率、无进展生存期、总生存期及微小残留病阴性率,但3至4级感染率略有增加。
要点
- 四药方案较三药方案提高总缓解率(RR 1.03,95%CI 1.01-1.05)和无进展生存期(HR 0.55,95%CI 0.46-0.66)。
- 四药方案提高10⁻⁵(RR 1.39)和10⁻⁶(RR 1.62)水平的微小残留病阴性率并改善总生存期(HR 0.65)。
- 四药方案较三药方案3至4级感染率略有增加(RR 1.22,95%CI 1.07-1.39)。
核心结论
- 在新诊断多发性骨髓瘤中,四药方案较三药方案改善总缓解率、微小残留病阴性率、无进展生存期和总生存期,3至4级感染率略有增加。
- 四药方案代表一种新的标准治疗,尤其在适合移植的新诊断多发性骨髓瘤患者中。
研究设计与样本
- 系统评价与Meta分析,检索Embase、MEDLINE、Web of Science、Cochrane Library、临床试验注册库及会议库(从建库至2024年1月24日)并补充2024年美国临床肿瘤学会会议摘要。
- 纳入7项随机对照试验共3716例新诊断多发性骨髓瘤患者,比较蛋白酶体抑制剂联合免疫调节药物方案与同方案加抗CD38单抗的四药方案。
主要发现
- 四药方案较三药方案提高总缓解率(RR 1.03,95%CI 1.01-1.05)。
- 四药方案较三药方案改善无进展生存期(HR 0.55,95%CI 0.46-0.66)和总生存期(HR 0.65,95%CI 0.53-0.79)。
- 四药方案较三药方案提高10⁻⁵水平微小残留病阴性率(RR 1.39,95%CI 1.23-1.58)和10⁻⁶水平微小残留病阴性率(RR 1.62,95%CI 1.36-1.94)。
- 四药方案较三药方案3至4级感染率略有增加(RR 1.22,95%CI 1.07-1.39)。
关键数值与推荐
- 总缓解率:四药方案 vs 三药方案 RR 1.03(95%CI 1.01-1.05)。
- 无进展生存期:四药方案 vs 三药方案 HR 0.55(95%CI 0.46-0.66)。
- 总生存期:四药方案 vs 三药方案 HR 0.65(95%CI 0.53-0.79)。
- 10⁻⁵微小残留病阴性率:四药方案 vs 三药方案 RR 1.39(95%CI 1.23-1.58);10⁻⁶微小残留病阴性率:RR 1.62(95%CI 1.36-1.94)。
- 3至4级感染率:四药方案 vs 三药方案 RR 1.22(95%CI 1.07-1.39)。
临床怎么用
- 作者认为四药方案代表一种新的标准治疗,尤其在适合移植的新诊断多发性骨髓瘤患者中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Quadruplet regimens (anti-CD38 monoclonal antibodies [mAbs] with proteasome inhibitor [PI] and immunomodulatory drugs [IMiDs]) are increasingly being investigated in newly diagnosed multiple myeloma (NDMM). The objective of our study was to conduct a systematic review and meta-analysis to measure the efficacy and toxicity of quadruplet regimens used in NDMM. Embase, MEDLINE, Web of Science, Cochrane Library, clinical trial registries, and meeting libraries from inception to 24 January 2024, in addition to American Society of Clinical Oncology conference abstracts 2024, were searched using terms reflecting multiple myeloma and components of the quadruplet regimen. Included studies were randomized controlled trials (RCTs) that compared backbone regimens consisting of a PI and IMiD vs the same regimen plus an anti-CD38 mAb in NDMM. We identified 7 RCTs including 3716 patients. Compared with triplets, quadruplets increase the overall response rate (ORR; relative risk [RR], 1.03; 95% confidence interval [CI], 1.01-1.05) and progression-free survival (PFS; hazard ratio [HR], 0.55; 95% CI, 0.46-0.66). Quadruplets increase the rates of minimal residual disease (MRD) negativity at 10-5 (RR, 1.39; 95% CI, 1.23-1.58) and 10-6 (RR, 1.62; 95% CI, 1.36-1.94). Quadruplets improve overall survival (OS; HR, 0.65; 95% CI, 0.53-0.79). There was a slight increase in the rates of grade 3 to 4 infections (RR, 1.22; 95% CI, 1.07-1.39) noted with quadruplets compared with triplets. Overall, in this meta-analysis, quadruplets were associated with improved efficacy including ORR, MRD negativity, PFS, and OS, with a slight increase in infection rates. Quadruplet regimens represent a new standard of care, particularly in transplant-eligible NDMM.
引用
- Ebraheem MS, Chakraborty R, Rochwerg B, et al. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2024. PMID: 39348665. doi:10.1182/bloodadvances.2024014139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。